An update by Genzyme regarding treatment for Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup that damages muscles and can affect breathing and, in some cases, the heart.. Q: What is the status of the Pompe program? Genzyme has

IBaarn, October 2nd 2002 Dear IPA members, Herewith I would like to inform you about the IPA/Genzyme telephone conference of

In July 2002, Genzyme began the transition of the nine transgenic (rabbit derived enzymeA protein that helps the body carry out chemical reactions.) patients to the CHO derived product.

Board members of the IPA, the International Pompe Association, met with key representatives of Genzyme in Cambridge, Massachusetts on April

Excerpt From Genzyme’s April 17, 2002 Press Release Pompe Update Genzyme is moving forward aggressively with its program to develop

Following is a letter sent to the IPA by Jan van Heek, Executive Vice President of Genzyme, for release prior

The first official IPA Board Meeting occurred in Rotterdam, The Netherlands on Feb. 18-19, 2002. Future agendas were planned and

The International Pompe Association (IPA) board will meet on February 18-19th, 2002. Representatives of scientific/medical teams and Genzyme will attend.

October 2001—CAMBRIDGE, Mass.—Genzyme Corporation announced today that it has acquired certain assets of Pharming N.V., the Belgian subsidiary of the

The first AMDA Patient Conference was held in San Antonio, Texas on September 28-30, 2001. It was attended by approximately